NR2E1 and prostate carcinoma: Recently, we have demonstrated that TLX, which is upregulated in prostate cancer, can promote its initiation and progression by repression of oncogene-induced senescence via its differential co-regulation of senescence-regulatory genes CDKN1A and SIRT1 [32].